Palmen F M
Respiration. 1983;44(2):103-8. doi: 10.1159/000194535.
Oral ketotifen (Zaditen) 1 mg twice daily was compared with inhaled disodium cromoglycate (DSCG; Lomudal) 20 mg four times a day in an open study with two matched groups of patients treated for protection against allergen-induced bronchoconstriction. 9 patients were treated with ketotifen and 9 patients with DSCG for 4 weeks. The comparison of the differences between the mean values at provocation, at the start of the study, and after a 4-week drug treatment shows that the drugs are equally effective on the forced expiratory volume at 1 s. Ketotifen is less effective on the vital capacity than DSCG. Patients' and investigator's assessment of tolerability and efficacy of the two therapies were similar. It is concluded that ketotifen is as effective as DSCG in protecting asthmatic patients antigen bronchial challenge and is tolerated as well as DSCG.
在一项开放性研究中，将两组匹配的患者用于预防变应原诱发的支气管收缩，一组患者口服酮替芬（扎迪特）1毫克，每日两次，另一组患者吸入色甘酸钠二钠（DSCG；洛穆达）20毫克，每日四次。9名患者接受酮替芬治疗，9名患者接受DSCG治疗，为期4周。对激发试验时、研究开始时以及4周药物治疗后的平均值差异进行比较，结果显示两种药物对1秒用力呼气量的疗效相同。酮替芬对肺活量的疗效不如DSCG。患者和研究者对两种治疗的耐受性和疗效评估相似。得出的结论是，酮替芬在保护哮喘患者免受抗原支气管激发方面与DSCG同样有效，并且耐受性与DSCG相当。
